HealthSocial Issues
News 5 of 28

Tata Memorial Centre Study Finds Cancer Immunotherapy Costs ₹60 Lakh for 6 Months, 80x Average Income, Beyond Ayushman Bharat

Target:UPSC GS-IMPSCTeachingSSC GAPrelims HighMains HighStatic GK Link
04 Mar 2026
~2 min
Source: Indian Express
Key Data:₹60-65 lakh (6-month pembrolizumab)80x average monthly income₹12-15 lakh (6-month nivolumab)18-22 patients (cheaper therapy per 1 immunotherapy patient)
Bodies:Tata Memorial Centre (TMC)Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)Cancer Policy & Global Health, Kings Institute of Cancer Policy, London
Practice MCQs from today's news ▸
What This Article Covers

1.A study by Tata Memorial Centre (TMC) and ACTREC found immunotherapy drugs like pembrolizumab and nivolumab are unaffordable for most head and neck cancer patients in India.

2.A six-month course of pembrolizumab costs ₹60-65 lakh, which is nearly 80 times the average monthly income, pushing families into poverty.

3.The study calls for urgent pricing reforms, including central price negotiations, faster approval of biosimilars, and evidence-based guidelines for drug use to improve equity in cancer care.

The Big Picture
Prelims · HighMains · High

A landmark study by Tata Memorial Centre reveals immunotherapy drugs for head and neck cancer remain prohibitively expensive in India, costing ₹60-65 lakh for a six-month course. This highlights a critical gap in healthcare affordability and policy, as these life-saving treatments are not covered under Ayushman Bharat, forcing patients into catastrophic out-of-pocket expenditure.

Exam Lens

Quick Exam Facts From News

Drug Cost (6 months)Pembrolizumab: ₹60-65 lakh; Nivolumab: ₹12-15 lakh
Cost-to-Income RatioPembrolizumab cost is 80x average monthly income
Study Published InHead & Neck journal
Lead InstitutionsTata Memorial Centre (TMC), Mumbai & ACTREC, Navi Mumbai
Alternative Treatment CostMoney for 1 pembrolizumab patient could treat 18-22 patients with cheaper targeted therapy

1-Minute Revision

  • ›Drug Cost (6 months): Pembrolizumab: ₹60-65 lakh; Nivolumab: ₹12-15 lakh
  • ›Cost-to-Income Ratio: Pembrolizumab cost is 80x average monthly income
  • ›Target this Data: Pembrolizumab costs ₹60-65 lakh for a 6-month course.
  • ›Target this Nodal Body: Tata Memorial Centre (TMC) and ACTREC conducted the study.
  • ›Target this Policy Gap: Immunotherapy drugs are not covered under Ayushman Bharat PM-JAY.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

Q1Static LinkageEasy

The Tata Memorial Centre (TMC), which led the study on cancer drug affordability, operates under which government department?

Q2Statement-basedHard

Consider the following statements regarding the findings of the Tata Memorial Centre study on cancer drug affordability:

1. The study found that immunotherapy drugs like pembrolizumab are covered under the Ayushman Bharat scheme for head and neck cancer patients.

2. The cost of a six-month course of pembrolizumab in India is approximately 80 times the average monthly income of a patient.

3. The study was conducted in collaboration with the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC).

Which of the statements given above is/are correct?

Q3Data-centricMedium

According to the study published in the Head & Neck journal, what is the approximate cost of a six-month course of the immunotherapy drug nivolumab (Opdivo) in India?

Q4Application/ImpactMedium

What is the primary reason highlighted in the study for the inaccessibility of modern immunotherapy drugs for head and neck cancer patients in India?

All 15 MCQs ▸
You finished this topic
Explore Related Topics
Related Current Affairs
Social Issues Current Affairs

CMS-E 2025: Govt School Education Costs ₹4,757/yr; Private Coaching Largest at ₹1,855

This article reveals that while government school education is nominally 'free', families spend an average of ₹4,757 per child annually, with private coaching (₹1,855) being the largest component. Only 27% of students take coaching, but it accounts for 40% of total costs. The RTE Act's narrow definition of 'free' only covers the course fee (₹324), leaving the bulk of expenses unaddressed. This data is critical for understanding the real cost of education and the limitations of current policy.

Polity Current Affairs

Centre Seeks SC Exemption for CSE 2025, 2026 from OBC Creamy Layer Income Test Retroactivity

The Centre has urged the Supreme Court to keep CSE 2025 and 2026 out of the Rohith Nathan judgment's retrospective operation, allowing the older OBC creamy layer income test to continue. It warns that retrospective application would hit 3.7 lakh OBC recruitments since 2016 and trigger widespread litigation across Railways, Banks, Posts and paramilitary.

Social Issues Current Affairs

Ayushman Bharat PM-JAY: 60 Cr Beneficiaries, 13 Cr Treatments, ₹2 Lakh Crore Savings in 8 Years

Ayushman Bharat PM-JAY, the world's largest health insurance scheme, completes 8 years with 60 crore beneficiaries, 13 crore hospitalisations, and ₹2 lakh crore in savings. The scheme provides ₹5 lakh cashless cover per family annually, with 48.5 crore Ayushman cards issued. This news is significant for exams as it tests understanding of India's health infrastructure and government welfare schemes.

Economy Current Affairs

Centre Mandates 60:40 Centre-State Funding Split for VB-G RAM-G Rural Employment Scheme

The Centre has shifted the funding pattern of the National Rural Employment Guarantee Scheme (now VB-G RAM-G) from 100% central funding to a 60:40 Centre-State split (90:10 for Himalayan/Northeast states). This marks a major fiscal federalism change, with states allocating full 40% despite political opposition. Essential for Prelims (ratio, scheme name) and Mains (fiscal federalism, rural wage floor).

Polity Current Affairs

SC Rules on OBC Creamy Layer Income Test: Salaries Excluded, Centre Seeks Clarification on Retrospective Impact

The Supreme Court in March 2026 ruled that while determining OBC creamy layer status, income from salaries and agriculture must be excluded from the income/wealth test. The Centre now seeks clarification, arguing retrospective implementation from 2012 is 'extremely difficult' and would cause a cascading effect on recruitments and admissions.

Polity Current Affairs

FSDA Cancels 16 Pharma Licences, Suspends Pfizer Depot in Bengaluru Fake Drug Bust Worth ₹5 Cr

Karnataka FSDA has cancelled 16 pharma licences and suspended 8 others, including Pfizer's depot, after seizing counterfeit drugs worth ₹5 crore from farmhouses. The racket involved refilling cheap drugs into vials of expensive MNC brands, posing a serious public health risk. This highlights gaps in drug regulatory enforcement and the need for stricter supply chain vigilance.

Polity Current Affairs

SC Proposes Exempting Current Class 6 from Three-Language Policy; Centre Seeks More Time

The Supreme Court has proposed exempting the current Class 6 batch from the mandatory three-language policy, suggesting implementation from January 1, 2027. The Centre has sought more time to decide, while the court has asked for details on teacher availability and infrastructure.

Polity Current Affairs

MahaRERA Strikes Down Builder's Unilateral Cancellation Clause, Orders Interest from Oct 2023 Under RERA Act

MahaRERA has declared illegal a contractual clause that allowed a builder to unilaterally cancel a flat allotment via Power of Attorney, reinforcing statutory safeguards under the RERA Act. The developer was ordered to pay interest for delayed possession from October 1, 2023. This ruling is a key example of regulatory protection for homebuyers and a must-know for exams covering RERA, consumer rights, and state-level governance.

Modern cancer drugs still…, Current Affairs for Exams